Copyright
©The Author(s) 2017.
World J Clin Oncol. Jun 10, 2017; 8(3): 241-248
Published online Jun 10, 2017. doi: 10.5306/wjco.v8.i3.241
Published online Jun 10, 2017. doi: 10.5306/wjco.v8.i3.241
Table 3 Fertility Preservation options for reproductive age women with breast cancer
Fertility preservation option | Current status | Advantages | Disadvantages |
Embryo Cryopreservation | Established | Highest cumulative pregnancy rates | Requires about two weeks delay in the initiation of cancer treatment |
Requires hormonal stimulation for oocyte retrieval | |||
Requires in vitro fertilization with male partner or donor sperm | |||
Oocyte Cryopreservation | Established | No need for male partner or sperm donor | Requires about two weeks delay in the initiation of cancer treatment |
Requires hormonal stimulation for oocyte retrieval | |||
Ovarian Tissue Cryopreservation and Transplantation | Currently experimental, may change as success rates are rising | No need for hormonal stimulation | Requires outpatient laparoscopic surgery for ovarian tissue harvesting and subsequent transplantation |
No need to significantly delay in the initiation of chemotherapy | |||
No need for male partner or sperm donor |
- Citation: Taylan E, Oktay KH. Current state and controversies in fertility preservation in women with breast cancer. World J Clin Oncol 2017; 8(3): 241-248
- URL: https://www.wjgnet.com/2218-4333/full/v8/i3/241.htm
- DOI: https://dx.doi.org/10.5306/wjco.v8.i3.241